Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Neupro Filed With the FDA for Restless Legs Syndrome
Dec. 14, 2007
The U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental new drug application (sNDA) for the use of Neupro (Rotigotine Transdermal System) as a treatment for moderate-to-severe Restless Legs Syndrome (RLS).
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing